Tadalafil Brand Names: Major Products and Market Context

Major Tadalafil Products at a Glance

Cialis, Adcirca and TADLIQ provide three useful examples of how one active molecule can exist in different finished-product contexts. Cialis is an oral tablet product for ED/BPH, while Adcirca and TADLIQ use tadalafil in PAH treatment but differ in dosage form.

Generic tadalafil should be treated separately from a trade-name list. An FDA-approved generic is defined by its approved application, dosage form, strength and reference-product relationship rather than by simply carrying tadalafil somewhere on the label.

Cialis: The Best-Known Tadalafil Brand for ED and BPH

Cialis is the best-known tadalafil trade name in the erectile-dysfunction market. Current U.S. labeling identifies it as tadalafil tablets indicated for ED, the signs and symptoms of BPH and combined ED/BPH.

Its treatment frameworks include as-needed ED dosing and once-daily regimens, so the brand is associated with both event-based and continuous tadalafil use. The current U.S. supplied-tablet section lists 5 mg, 10 mg and 20 mg tablets, while the dosing instructions also retain a 2.5 mg once-daily ED starting dose.

Product-specific formulation, dosing and label detail belongs on the Cialis page rather than being repeated throughout this brand hub.

Adcirca: Tadalafil in a Pulmonary Arterial Hypertension Context

Adcirca also contains tadalafil, but its U.S. product identity is built around pulmonary arterial hypertension rather than ED or BPH. Current labeling indicates Adcirca for WHO Group 1 PAH to improve exercise ability.

Adcirca is supplied as a 20 mg tablet, while the standard PAH regimen is 40 mg once daily as two 20 mg tablets. The dose and indication therefore cannot be inferred simply from the fact that a Cialis tablet may also contain 20 mg tadalafil.

The product-level PAH details are covered on the Adcirca page, while Cialis vs Adcirca explains the brand-to-brand distinction.

TADLIQ: Tadalafil as an Oral Suspension

TADLIQ demonstrates why tadalafil brand names cannot be understood only as different tablet labels. It is an FDA-approved tadalafil oral suspension containing 20 mg per 5 mL and is indicated for WHO Group 1 pulmonary arterial hypertension to improve exercise ability.

Current labeling uses a standard 40 mg once-daily regimen, corresponding to 10 mL of the suspension, with or without food. The bottle must be shaken before administration, and the liquid formulation has its own excipient, measuring and handling characteristics.

TADLIQ is therefore not 'liquid Cialis.' It contains the same active molecule but belongs to a PAH-specific product and formulation context, covered in more depth on the TADLIQ page.

Same Tadalafil Does Not Mean Same Product

The active pharmaceutical ingredient is identical across Cialis, Adcirca and TADLIQ: tadalafil. The brands therefore share the core PDE5 mechanism and many molecule-level pharmacologic and safety properties.

Finished-product identity adds another layer. A brand determines formulation, supplied strength, indication-specific instructions, packaging and labeling, and those differences can materially change how the same molecule is used.

The safest interpretation is therefore to separate active-drug identity from finished-product identity.

A Brand Name and a Generic Name Are Different Concepts

Tadalafil is the nonproprietary active-ingredient name. Cialis, Adcirca and TADLIQ are proprietary product names attached to specific tadalafil formulations and label contexts.

An FDA-approved generic tadalafil product is different again: it is approved through an ANDA and must satisfy FDA requirements such as the same active ingredient, corresponding strength, dosage form and route as its reference product, together with bioequivalence and manufacturing-quality requirements.

Generic fundamentals are covered on the generic tadalafil page; this hub uses generic products mainly to explain why a list of tadalafil brand names is not the same thing as a list of every tadalafil product.

Not Every FDA-Approved Tadalafil Generic Is a 'Generic Cialis'

Tadalafil has more than one reference-product context in the United States. FDA therapeutic-equivalence records distinguish Cialis-related tadalafil tablets from Adcirca-related tadalafil tablets, reflecting different reference products and approved treatment contexts.

That means the phrase 'generic Cialis' should be used more narrowly than 'generic tadalafil.' A tadalafil product should be confirmed as therapeutically equivalent to the appropriate Cialis reference context before being described as a U.S. generic counterpart to Cialis.

The distinction is examined in detail on tadalafil vs Cialis.

The Indication Cannot Be Inferred From Tadalafil Alone

Tadalafil is used across several clinical contexts, but the exact finished product determines which indication appears in its label. Cialis places tadalafil in ED/BPH treatment, whereas Adcirca and TADLIQ place it in PAH treatment.

This is particularly important when the same numerical strength appears in different products. A 20 mg Cialis tablet used in an as-needed ED framework and a 20 mg Adcirca tablet contributing to a 40 mg PAH regimen contain the same amount of tadalafil but do not carry the same treatment instruction.

Molecule-level indication context is covered on tadalafil for ED and BPH and tadalafil for pulmonary hypertension.

Adcirca and TADLIQ Share the PAH Indication but Not the Same Dosage Form

Adcirca and TADLIQ both place tadalafil in WHO Group 1 PAH treatment and use a standard 40 mg once-daily framework. Their principal finished-product difference is the dosage form: Adcirca is a 20 mg tablet, while TADLIQ is a 20 mg/5 mL oral suspension.

That distinction can matter for administration, measurement, excipients and handling even though the active ingredient and target total PAH dose are the same. TADLIQ also has formulation-specific instructions such as shaking the suspension before use.

They should therefore be described as separate tadalafil products within the same disease context rather than as identical packages of the same medication.

Tadalafil Brand Names Vary by Country

Commercial drug names are jurisdiction specific. Cialis has had broad international recognition, while other markets contain locally authorized tadalafil brands, generic products and branded generics that may not use the names familiar from the United States.

A medicine can be legitimately approved by another national regulator without having an FDA-approved U.S. application. Conversely, the fact that a foreign package says tadalafil does not establish the U.S. reference product, therapeutic-equivalence code, manufacturing application or indication.

For that reason, a global tadalafil brand list should identify its jurisdiction and regulatory source rather than combining names from pharmacies, marketplaces and search results into one supposedly universal list.

Indian Branded Generics Are a Separate Tadalafil Market Category

India has a large branded-generic pharmaceutical market, so tadalafil may be sold under proprietary trade names even when the underlying medicine is a generic product. That commercial structure differs from the common U.S. pattern in which many generics are recognized primarily by the nonproprietary name plus manufacturer or labeler.

An Indian tadalafil brand should not automatically be called an FDA-approved 'generic Cialis.' Its manufacturer, formulation, strength, local authorization and any separate U.S. approval must be verified independently.

Because the Indian market contains many products and changes over time, individual names belong on the dedicated Indian tadalafil brands page rather than turning this global hub into an unverified catalogue.

Brand Recognition Is Not a Standalone Quality Test

A familiar brand name can help identify a specific finished product, but familiarity alone does not determine medicine quality. In the United States, FDA-approved branded and generic products are subject to regulatory requirements for identity, strength, quality, manufacturing and ongoing oversight.

Likewise, an unfamiliar generic tablet is not automatically lower quality because it lacks the Cialis name. FDA-approved generics must meet the agency's scientific and manufacturing standards and are expected to provide the same clinical benefit as their appropriate reference products.

The critical qualifier is approved product status: those statements about FDA standards should not be automatically extended to unverified foreign, compounded or online products.

Core Tadalafil Safety Follows the Molecule, While Instructions Follow the Product

Because Cialis, Adcirca and TADLIQ all contain tadalafil, major molecule-level safety principles overlap. Their labels contraindicate organic nitrates and guanylate cyclase stimulators, and all operate within the broader tadalafil risks involving hypotension, hypersensitivity and other PDE5-related warnings.

Product-specific instructions still matter because dose, indication and formulation differ. TADLIQ and Adcirca use PAH-specific dose and interaction frameworks, while Cialis includes ED/BPH-specific counseling and dosing rules.

For molecule-level depth, use the tadalafil contraindications and drug interactions pages rather than assuming one brand label can substitute for another.

Multiple Tadalafil Names Do Not Mean the Products Are Automatically Interchangeable

Brand names are shorthand for specific approved products, not permission to transfer doses or indications between them. Cialis, Adcirca and TADLIQ all deliver tadalafil, but a prescription written in one product context should not be reinterpreted solely from the shared active-ingredient name.

The clearest example is PAH versus ED: 40 mg once-daily tadalafil is a PAH regimen under Adcirca or TADLIQ labeling, not a standard Cialis ED regimen. Likewise, a liquid PAH product should not be treated as though it were simply a different packaging format for Cialis.

Interchangeability questions require the exact product, formulation, indication and regulatory-equivalence relationship.

How to Verify a Tadalafil Brand or Product

A reliable product check starts with the exact trade or generic name, active ingredient, strength or concentration, dosage form, manufacturer or labeler and country of authorization. In the United States, the NDC and official labeling can further identify the marketed product.

For FDA approval or therapeutic-equivalence questions, official FDA resources and the Orange Book are more useful than reseller descriptions or informal lists. Outside the United States, the relevant national regulator should be checked because FDA status cannot be inferred from foreign authorization.

This product-level approach also helps distinguish a legitimate international brand from an unverified online item that merely uses a familiar tadalafil name.

Common Misunderstandings About Tadalafil Brand Names

The most common mistake is treating tadalafil, Cialis and every tadalafil trade name as interchangeable synonyms. Tadalafil is the active ingredient, while each branded or generic finished product has its own regulatory and formulation context.

It is also incorrect to call every tadalafil tablet 'generic Cialis,' to assume Adcirca is a stronger version of Cialis, or to describe TADLIQ as liquid Cialis. International brand names add another layer because approval in one country does not establish FDA approval in the United States.

A useful tadalafil brand list therefore needs fewer verified categories and more regulatory context, not the longest possible collection of trade names.

Key Takeaways: Tadalafil Brand Names

Tadalafil is the active ingredient, while Cialis, Adcirca and TADLIQ are distinct branded finished products. Cialis places tadalafil in ED/BPH treatment, Adcirca uses a tablet formulation for PAH and TADLIQ uses an oral suspension for PAH.

FDA-approved generic tadalafil adds a separate regulatory category, and the exact reference-product context matters before a product is described as a generic counterpart to Cialis or another tadalafil brand. Brand name, active ingredient, dosage form, indication and therapeutic equivalence are related concepts but are not interchangeable terms.

Globally, tadalafil trade names vary by country, and branded generics are particularly important in markets such as India. A reliable brand comparison should therefore identify jurisdiction and regulatory status rather than presenting an unverified exhaustive worldwide list.